Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
34 studies found for:    " August 03, 2011":" September 02, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Download search resultsDownload the search results for:
" August 03, 2011":" September 02, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION] (34 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Recruiting Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects
Condition: HIV Infections
Interventions: Biological: HIVAX;   Biological: saline solution;   Biological: Saline solution
2 Recruiting the ANRS CO21 " Extreme " Cohort (CODEX)
Condition: HIV Infection
Intervention: Biological: blood sampling
3 Completed Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)
Condition: HIV Infections
Interventions: Biological: Sub C gp140 Vaccine;   Biological: MF59C.1 Adjuvant;   Other: Sodium chloride
4 Completed An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART
Condition: Human Immunodeficiency Virus; HIV
Interventions: Drug: Darunavir/Ritonavir (DRV/r);   Drug: Efavirenz (EFV)
5 Completed Immediate Versus Deferred Antiretroviral Therapy in HIV-infected Patients Presenting With Acute AIDS-defining Events
Condition: HIV-Infection
Intervention: Other: Time of starting antiretroviral therapy
6 Completed Safety Study of Maraviroc's Effect on Human Osteoclasts
Conditions: HIV Infections;   AIDS
Intervention: Drug: Maraviroc
7 Terminated Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy
Conditions: Human Immunodeficiency Virus;   Lipohypertrophy
Intervention: Drug: Raltegravir-Maraviroc
8 Unknown  HEART to HAART: Smartphone Intervention to Improve HAART Adherence for Drug Users
Conditions: HIV;   Drug Use Disorders
Interventions: Behavioral: HEART to HAART;   Behavioral: adherence counseling with the addition of smartphone control
9 Completed DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects
Condition: HIV
Interventions: Drug: Twice-daily Darunavir/ritonavir;   Drug: Once-daily Darunavir/ritonavir
10 Completed Moringa Oleifera- Antiretroviral Pharmacokinetic Drug Interaction
Condition: HIV
Intervention: Dietary Supplement: Moringa oleifera
11 Completed
Has Results
Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers
Conditions: Hepatitis C;   HIV
Intervention: Drug: boceprevir; etravirine
12 Completed
Has Results
Home Assessment and Initiation of Antiretroviral Therapy for HIV in Malawi
Condition: HIV
Interventions: Other: Home assessment and initiation of ART;   Other: Clinic-based ART assessment and initiation
13 Completed Targeting Interventions at Venues Where Risk of HIV Transmission is High
Condition: HIV
Intervention: Other: Condom distribution and peer education
14 Completed HCV/HIV Coinfection: Antiviral Therapy and Fibrosis
Conditions: HIV Infection;   Hepatitis C
Intervention:
15 Unknown  Drug Exposure Registry for GSK2248761, an Investigational NNRTI
Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: GSK2248761
16 Completed AIMS Study: Improving HIV Treatment Adherence
Condition: HIV
Interventions: Behavioral: Treatment as usual;   Behavioral: AIMS intervention
17 Completed Integrated Mental Health Treatment & HIV Prevention for Court-Involved Youth
Condition: HIV Prevention
Interventions: Behavioral: Integrated treatment program;   Behavioral: Treatment as Usual
18 Completed Contraception and Menstrual Cycle Effect on Pharmacokinetics, Pharmacodynamics and Safety in Tenofovir Vaginal Gel Use
Condition: HIV Prevention
Interventions: Drug: Tenofovir 1% vaginal gel;   Drug: Depo-medroxyprogesterone acetate (DMPA);   Drug: Oral contraceptive: LNG 150 mcg and EE 30 mcg
19 Completed Drug Interaction Study Between Dolutegravir and Prednisone
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: Dolutegravir;   Drug: Prednisone
20 Completed A Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular and Subcutaneous Long Acting GSK1265744 in Healthy Subjects
Condition: Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions: Drug: GSK1265744 injectable suspension;   Other: Placebo to match injectable suspension

   Previous Page Studies Shown (1-20) Next Page (21-34) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.